Clinical trialNCT02871791CompletedPhase 1/PHASE2Interventional

Palbociclib With Everolimus + Exemestane In BC

SponsorDana-Farber Cancer InstituteEnrollment41Hormone Receptor (HR)-Positive Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Sara Tolaney, MD
Dana-Farber Cancer Institute
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Dana-Farber Cancer Institute
Boston, Massachusetts, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Everolimus →Exemestane →Palbociclib →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 24 Aug 2016
Primary completion: 3 Dec 2020
Completion: 30 Sept 2021
Last update posted: 29 Aug 2022
Registered enrollment: 41
Registry id: NCT02871791

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.